Related Experiment Video
Updated: Jul 9, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma
Mia C Weiss1,2, Vanessa Eulo3, Brian A Van Tine1,2,4
1Washington University in St. Louis, School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, Missouri.
Abstract:
Dedifferentiated liposarcoma (DDLPS) has an appealing therapeutic target due to its CDK4 amplification on chromosome 12q. The understanding of geroconversion from quiescent cells to senescent cells defines a patient's response to CDK4 inhibitors. This new observation will inform not only the ongoing phase III clinical trial of abemaciclib, but all future clinical trials in DDLPS. See related article by Gleason et al., p. 703.
More Related Videos
08:56Simultaneous Imaging and Flow-Cytometry-based Detection of Multiple Fluorescent Senescence Markers in Therapy-Induced Senescent Cancer Cells
Published on: July 12, 2022
14:01Far-Red Fluorescent Senescence-Associated β-Galactosidase Probe for Identification and Enrichment of Senescent Tumor Cells by Flow Cytometry
Published on: September 13, 2022
Related Concept Videos
Multipotency of Hematopoietic Stem Cells
Abnormal Proliferation